Corvus Pharmaceuticals is a clinical-stage biopharmaceutical company that focuses on the development of innovative therapies for the treatment of cancer
The company is primarily engaged in the discovery and development of immuno-oncology products, aiming to harness the body’s immune system to fight against various types of tumors. Corvus leverages its expertise in biologic compounds to create targeted treatments that enhance immune response while minimizing side effects. Through its ongoing research and clinical trials, the company seeks to provide new options for patients with unmet medical needs in oncology.
Investors and traders are closely monitoring the gap up and gap down stocks in today's session on Wednesday. Let's explore the market movements and identify the stocks with significant gaps.
Research and development expenses in the reported quarter rose by $2 million, primarily due to increased spending on the soquelitinib clinical trial for T-cell lymphoma.
Companies Reporting Before The Bell • Tencent Music Enter Gr (NYSE:TME) is projected to report quarterly earnings at $0.14 per share on revenue of $931.97 million.
